EMCURE

Emcure Pharmaceuticals Share Price

 

 

Invest in Emcure Pharmaceuticals with 3.26X leverage

Invest with MTF

Performance

  • Low
  • ₹1,539
  • High
  • ₹1,575
  • 52 Week Low
  • ₹889
  • 52 Week High
  • ₹1,575
  • Open Price₹1,551
  • Previous Close₹1,551
  • Volume310,254
  • 50 DMA₹1,427.82
  • 100 DMA₹1,393.29
  • 200 DMA₹1,362.76

Investment Returns

  • Over 1 Month + 9.18%
  • Over 3 Month + 17.3%
  • Over 6 Month + 15.89%
  • Over 1 Year + 16.23%

Smart Investing Starts Here Start SIP with Emcure Pharmaceuticals for Steady Growth!

Invest Now

Emcure Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 37.5
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 29,774
  • P/B Ratio
  • 6.3
  • Average True Range
  • 52.6
  • EPS
  • 42.32
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 28.24
  • RSI
  • 67.78
  • MFI
  • 69.14

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,570.60
+ 20 (1.29%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,472.99
  • 50 Day
  • ₹1,427.82
  • 100 Day
  • ₹1,393.29
  • 200 Day
  • ₹1,362.76

Resistance and Support

1561.6 Pivot Speed
  • R3 1,619.80
  • R2 1,597.40
  • R1 1,584.00
  • S1 1,548.20
  • S2 1,525.80
  • S3 1,512.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Emcure Pharmaceuticals manufactures and markets a wide range of pharmaceutical products, including generics, biosimilars, and injectables. With a global presence in 70+ countries, it focuses on affordable healthcare solutions across therapeutic areas like cardiology, oncology, and women’s health.

Emcure Pharmaceuticals Ltd has an operating revenue of Rs. 8,449.23 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 12% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 18% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 18 indicates it belongs to a strong industry group of Medical-Supplies and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Emcure Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-08-07 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-02-06 Quarterly Results
2024-11-07 Quarterly Results
Date Purpose Remarks
2025-08-14 FINAL Rs.3.00 per share(30%)Final Dividend
View Emcure Pharmaceuticals Dividend History Arrow

Emcure Pharmaceuticals F&O

Emcure Pharmaceuticals Shareholding Pattern

77.88%
3.58%
0.48%
3.29%
0.01%
6.23%
8.53%

About Emcure Pharmaceuticals

  • NSE Symbol
  • EMCURE
  • BSE Symbol
  • 544210
  • Managing Director & CEO
  • Mr. Satish Ramanlal Mehta
  • ISIN
  • INE168P01015

Similar Stocks to Emcure Pharmaceuticals

Emcure Pharmaceuticals FAQs

Emcure Pharmaceuticals share price is ₹1,570 As on 15 January, 2026 | 15:31

The Market Cap of Emcure Pharmaceuticals is ₹29774.3 Cr As on 15 January, 2026 | 15:31

The P/E ratio of Emcure Pharmaceuticals is 37.5 As on 15 January, 2026 | 15:31

The PB ratio of Emcure Pharmaceuticals is 6.3 As on 15 January, 2026 | 15:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23